Abstract Body

Studies of HIV DNA integration provide a rich example of how basic research can inform new therapies, and how findings from translational implementation in turn can pose new questions. To replicate, a retrovirus such as HIV must integrate a DNA copy of the viral RNA genome into host cells. Establishing methods for analyzing HIV DNA integration in vitro helped launch the development of the integrase inhibitors, a pivotal class of antiretroviral drugs. Coming from another direction, studies of HIV integration target site selection have provided additional insights into mechanisms of replication and control of viral replication. Early studies showed that HIV favors integration in active transcription units, which makes sense for facilitating efficient HIV gene expression after integration. Further studies showed that tethering to cellular chromatin binding proteins contributed to targeting. Recent studies in people with HIV who effectively control virus show that distributions may be enriched in regions where the virus is poorly expressed due to aggressive selection by CD8+ T cells. These results have been recapitulated in various cell culture and animal models, allowing detailed mechanistic analysis. Studies of integration targeting also inform monitoring of human gene therapy, where insertional mutagenesis by gene transfer vectors is a concern. Recent studies suggest that HIV and retroviral vectors can carry out insertional mutagenesis in humans via four different mechanisms: enhancer insertion, promoter insertion, gene inactivation, and gene activation by mRNA 3’ end substitution. Stepping back, these mechanistic studies provide an overview of how basic research advances treatment of HIV, and contribute to the conceptual foundation for addressing many other disorders.